Novel Resveratrol Derivatives Induce Apoptosis and Cause Cell Cycle Arrest in Prostate Cancer Cell Lines
Background: Resveratrol (RV), a naturally occurring phytoalexin, exerts manifold biological effects against a variety of human tumor cell lines. In this study, the cytotoxic and biological effects of novel RV derivatives were investigated in prostate cancer cells. Materials and Methods: Cytotoxicity...
Saved in:
Published in: | Anticancer research Vol. 27; no. 5A; pp. 3459 - 3464 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Attiki
International Institute of Anticancer Research
01-09-2007
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: Resveratrol (RV), a naturally occurring phytoalexin, exerts manifold biological effects against a variety of human
tumor cell lines. In this study, the cytotoxic and biological effects of novel RV derivatives were investigated in prostate
cancer cells. Materials and Methods: Cytotoxicity of the compounds was assessed by clonogenic assays in PC-3, LNCaP and DU-145
human prostate cancer cell lines. Induction of apoptosis was studied by Hoechst-propidium-iodide double staining. Cell cycle
phase distribution of prostate cancer cells was analyzed using flow cytometry. Results: Methoxy- and hydroxy-substituted RV
derivatives exerted cytotoxic effects against all three cell lines. The most potent compounds, 3,3â²,4,4â²,5,5â²-hexahydroxy-stilbene
and 3,4,4â²,5-tetramethoxy-stilbene, induced apoptosis at concentrations lower than RV and caused cell cycle arrest in the
cell lines investigated. Conclusion: Introducing additional hydroxy- and methoxy-moieties to the stilbene ring of RV is capable
of enhancing its cytotoxic and pro-apoptotic effects in hormone-responsive and non-responsive prostate cancer cells. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 |